Regeneron Pharmaceuticals, Inc.
General ticker "REGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $95.7B (TTM average)
Regeneron Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -2.4%.
Estimated limits based on current volatility of 2.3%: low 541.45$, high 566.92$
Factors to consider:
- Earnings expected soon, date: 2025-04-29 bmo
- Company included in S&P500 list
- Company included in NASDAQ-100 index
- Company pays dividends (irregularly): last record date 2025-02-20, amount 0.88$ (Y0.16%)
- US accounted for 8.5% of revenue in the fiscal year ended 2024-12-31
- Current price 12.6% below estimated low
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [644.54$, 952.52$]
- 2025-12-31 to 2026-12-31 estimated range: [698.53$, 1012.41$]
Financial Metrics affecting the REGN estimates:
- Positive: Non-GAAP EPS, $ of 45.64 > 2.19
- Negative: Industry earnings per price (median), % of -27.42 <= 0
- Positive: Interest expense per share, $ of 0.51 <= 0.67
- Positive: Operating profit margin, % of 28.21 > 18.46
- Positive: Return on assets ratio (scaled to [-100,100]) of 10.46 > 6.86
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 77.74 > 63.75
- Positive: Inventory ratio change, % of 0.89 <= 1.05
Short-term REGN quotes
Long-term REGN plot with estimates
Financial data
YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
---|---|---|---|
Operating Revenue | $12,262.80MM | $13,119.30MM | $14,148.60MM |
Operating Expenses | $7,523.90MM | $9,072.20MM | $10,157.90MM |
Operating Income | $4,738.90MM | $4,047.10MM | $3,990.70MM |
Non-Operating Income | $119.90MM | $152.20MM | $789.20MM |
Interest Expense | $59.40MM | $73.00MM | $55.20MM |
R&D Expense | $3,847.60MM | $4,625.10MM | $5,233.00MM |
Income(Loss) | $4,858.80MM | $4,199.30MM | $4,779.90MM |
Taxes | $520.40MM | $245.70MM | $367.30MM |
Profit(Loss)* | $4,338.40MM | $3,953.60MM | $4,412.60MM |
Stockholders Equity | $22,664.00MM | $25,973.10MM | $29,353.60MM |
Inventory | $2,401.90MM | $2,580.50MM | $3,087.30MM |
Assets | $29,214.50MM | $33,080.20MM | $37,759.40MM |
Operating Cash Flow | $5,014.90MM | $4,594.00MM | $4,420.50MM |
Capital expenditure | $590.10MM | $926.40MM | $755.90MM |
Investing Cash Flow | $-3,784.60MM | $-3,185.10MM | $-2,468.10MM |
Financing Cash Flow | $-1,009.00MM | $-1,790.10MM | $-2,200.50MM |
Earnings Per Share** | $40.51 | $37.05 | $40.90 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.